The inactive ingredients that make up a major component of drug formulations may not be as inactive as previously thought, researchers report. According to a new study, some excipients generally considered inert - drug additives that include coloring agents, preservatives and fillers - can have activities on medically relevant molecular targets, affecting the function of enzymes, receptors and other proteins in unintended and perhaps harmful ways. While most excipients are truly inactive, the results identify those that merit further consideration and review. By mass, most drug products contain far more excipients than active pharmaceuticals. While classified as "inactive ingredients," excipients play key roles in a drug's pharmacokinetics, enhancing their overall deliverability and stability across a range of applications. Often, the safety and inert status of most excipients are evaluated in animal tolerability studies, where their general toxicity is evaluated. However, the potential for excipient interaction with molecular targets has lacked systematic investigation. Using large-scale computational screening and targeted experimental testing, Joshua Pottel and colleagues identified 134 previously unknown activities for 38 approved excipients, demonstrating that the "inactive" ingredients ubiquitous in many drugs have direct activity against biologically relevant molecules in vitro. Of these, Pottel et al. revealed that several excipients exhibit evidence predictive of tissue-level toxicity in cellular models. While most of these are suspected not to reach dangerous exposure levels, the results suggest that two - thimerosal and cetylpyridinium - are capable of reaching in vivo concentrations, that overlap their in vitro binding activity to the dopamine receptor D3. The findings indicate that while many excipients do not reach general circulation in vivo, several do, and may have unplanned pharmacology of their own.
###
Journal
Science